<SEC-DOCUMENT>0001171520-22-000346.txt : 20220525
<SEC-HEADER>0001171520-22-000346.hdr.sgml : 20220525
<ACCEPTANCE-DATETIME>20220525170120
ACCESSION NUMBER:		0001171520-22-000346
CONFORMED SUBMISSION TYPE:	DFAN14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20220525
DATE AS OF CHANGE:		20220525

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		22963884

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SINGER JULIAN D.
		CENTRAL INDEX KEY:			0001628706

	FILING VALUES:
		FORM TYPE:		DFAN14A

	MAIL ADDRESS:	
		STREET 1:		2200 FLETCHER AVENUE
		STREET 2:		SUITE 501
		CITY:			FORT LEE
		STATE:			NJ
		ZIP:			07024
</SEC-HEADER>
<DOCUMENT>
<TYPE>DFAN14A
<SEQUENCE>1
<FILENAME>eps10286.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 13.5pt Times New Roman,serif; margin: 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 13.5pt Times New Roman,serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 8pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 16pt Times New Roman,serif; margin: 0; text-align: center"><B>SCHEDULE 14A </B></P>

<P STYLE="font: 6pt Times New Roman,serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>Proxy Statement Pursuant to Section 14(a) of the </B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>(Amendment No. )</B></P>

<P STYLE="font: 12pt Arial,sans-serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0 0 2pt">Filed by the Registrant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: MS Gothic">&#9744;</FONT></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0 0 2pt">Filed by a Party other than the Registrant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: MS Gothic">&#9745;</FONT></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0 0 2pt">Check the appropriate box:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman,serif; margin-top: 0; margin-bottom: 2pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></TD><TD>Preliminary Proxy Statement</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman,serif; margin-top: 0; margin-bottom: 2pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></TD><TD>Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman,serif; margin-top: 0; margin-bottom: 2pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></TD><TD>Definitive Proxy Statement</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman,serif; margin-top: 0; margin-bottom: 2pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></TD><TD>Definitive Additional Materials</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman,serif; margin-top: 0; margin-bottom: 2pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: MS Gothic">&#9745;</FONT></TD><TD>Soliciting Material Pursuant to &sect;240.14a-12</TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>CATALYST BIOSCIENCES, INC.</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>(Name of Registrant as Specified in Its Charter)</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>JDS1, LLC</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>CCUR HOLDINGS, INC.</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>CIDM II, LLC</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>JULIAN D. SINGER</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>DAVID S. OROS</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>SHELLY C. LOMBARD</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>MATTHEW STECKER</B></P>

<P STYLE="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><B>IGOR VOLSHTEYN</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>(Name of Person(s) Filing Proxy Statement, if Other Than
the Registrant)</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0">Payment of Filing Fee (Check the appropriate box):</P>

<P STYLE="font: 12pt Arial,sans-serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 12pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-family: Times New Roman,serif"><FONT STYLE="font-family: MS Gothic">&#9745;</FONT></TD>
    <TD STYLE="width: 95%; font-family: Times New Roman,serif; text-align: justify">No fee required</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman,serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></TD>
    <TD STYLE="font-family: Times New Roman,serif">Fee paid previously with preliminary materials</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman,serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></TD>
    <TD STYLE="font-family: Times New Roman,serif">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11</TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">On May 9, 2022, JDS1, LLC, a Delaware limited liability
company (&ldquo;JDS1&rdquo;), CCUR Holdings, Inc., a Delaware corporation (&ldquo;<U>CCUR</U>&rdquo;), CIDM II, LLC, a Delaware limited
liability company (&ldquo;<U>CIDM II</U>&rdquo;), Julian D. Singer, David S. Oros, Shelly C. Lombard, Matthew Stecker, and Igor Volshteyn
(collectively, the &ldquo;<U>JDS1 Group</U>&rdquo;), filed a revised preliminary proxy statement and an accompanying revised preliminary
GOLD proxy card with the U.S. Securities and Exchange Commission (&ldquo;<U>SEC</U>&rdquo;) to be used solicit proxies from the stockholders
of Catalyst Biosciences, Inc., a Delaware Corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the Company&rsquo;s 2022
Annual Meeting of Stockholders, any special meeting held in lieu thereof, and at any and all adjournments or postponements thereof (the
&ldquo;<U>2022 Annual Meeting</U>&rdquo;).</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify"><B>Schedule 13D Amendment No. 13 Filed on May 25, 2022</B></P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">On May 25, 2022, the JDS1 Group filed Amendment No.
13 to its Schedule 13D with respect to the Company (the &ldquo;<U>Schedule 13D/A</U>&rdquo;). The following disclosure was included in
Item 4 of the Schedule 13D/A and is being included in this Schedule 14A because such disclosure may be deemed&nbsp;to be solicitation
material in connection with the JDS1 Group&rsquo;s plans to solicit proxies from the Company&rsquo;s stockholders for use at the 2022
Annual Meeting:</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify"><I>&ldquo;</I>Item 4 is hereby amended to add the following:</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">As previously disclosed, on May 9, 2022, JDS1 and the
other reporting persons named herein (collectively, the &ldquo;<U>JDS1 Group</U>&rdquo;) filed a revised preliminary proxy statement with
the SEC in connection with its plans to solicit proxies for the Issuer&rsquo;s 2022 Annual Meeting of Stockholders, any special meeting
held in lieu thereof, and at any and all adjournments or postponements thereof (the &ldquo;<U>2022 Annual Meeting</U>&rdquo;). At the
2022 Annual Meeting, the JDS1 Group will seek to have stockholders elect the three nominees, Shelly C. Lombard, Matthew Stecker, and Igor
Volshteyn (collectively, the &ldquo;<U>Nominees</U>&rdquo;), JDS1 has nominated for election to the Issuer&rsquo;s Board of Directors
(the &ldquo;<U>Board</U>&rdquo;) and approve a non-binding stockholder proposal requesting that the Board take the necessary steps to
declassify the Board (in a manner that does not affect the unexpired terms of the previously elected directors) and to require that all
directors stand for election annually, with such declassification of the Board done in the most expeditious manner available under the
Delaware General Corporation Law.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">On May 23, 2022, the Issuer publicly disclosed that,
on May 19, 2022, it had entered into and closed on an Asset Purchase Agreement with Vertex Pharmaceuticals Incorporated (&ldquo;<U>Vertex</U>&rdquo;),
pursuant to which Vertex acquired certain assets from the Issuer for $60 million in cash (the &ldquo;<U>Asset Sale</U>&rdquo;), with $5
million retained as a hold-back until one year after the closing to satisfy certain post-closing indemnification obligations. The Issuer
has provided very limited details regarding the Asset Sale and has not, as of the date hereof, publicly filed with the SEC a copy of the
Asset Purchase Agreement it signed with Vertex.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">The Issuer&rsquo;s announcement of the Asset Sale comes
nearly three years after JDS1, in its July 22, 2019 letter, first called upon the Issuer to retain a financial advisor to assist it in
exploring strategic alternatives, when the Shares&rsquo; closing price was $8.32 per share. While the per share price of the Shares has traded
up since the Issuer announced the Asset Sale, based on the per Share closing price of $1.34 on May 24, 2022, the per share price of the
Shares is still down approximately 84% since July 22, 2019, when JDS1 first called upon the Issuer to explore strategic alternatives.
The Reporting Persons believe that without its proxy contest presently pending to replace three members of the Board at the 2022 Annual
Meeting and, thereby, hold the Board accountable for the huge destruction of value that has occurred over the past year (as of close of
business on May 24, 2022, an approximately 67% decline from the per share closing price of $4.10 twelve months ago on May 25, 2021), the
Board may not have been as inclined to retain a financial advisor to explore strategic alternatives and it is possible that the Asset
Sale may not have occurred.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">The Reporting Persons are extremely concerned
that, as of the date hereof, the Issuer has not disclosed what it plans to do with the approximately $87 million in cash and cash
equivalents noted on its pro forma balance sheet, included as Exhibit 99.2 to the Current Report on Form 8-K/A that the Issuer filed
with the SEC on May 24, 2022, after giving effect to the net proceeds received from the Asset Sale. The Reporting Persons strongly
believe that most of the Issuer&rsquo;s cash and cash equivalents should be distributed to the Issuer&rsquo;s stockholders in as
expeditious a manner as possible and remain concerned with the possibility that the Issuer may have other plans for the use of such
funds. Accordingly, unless the Issuer moves quickly to publicly commit to an expeditious distribution of the cash and cash
equivalents on its pro forma balance sheet to the Issuer&rsquo;s stockholders, save for whatever it needs to retain to provide for
contingent liabilities and administrative expenses, the Reporting Persons&rsquo; plans for their proxy contest at the 2022 Annual Meeting
remain unchanged. The Reporting Persons also call upon the Issuer to schedule, and publicly announce a date, time, and place for,
the 2022 Annual Meeting and fix the associated record date therefor.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">Except as set forth in this Schedule 13D or such as
would occur upon or in connection with completion of, or following, any of the actions discussed in this Schedule 13D, no Reporting Person
has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4
of Schedule 13D. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors
including, without limitation, the Issuer&rsquo;s financial position and strategic direction, actions taken by the Board, the price levels
of the Shares, other investment opportunities available to the Reporting Persons, conditions in the securities markets and general economic
and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they
deem appropriate including, without limitation, engaging in communications with management and/or the Board, engaging in communications
with one or more stockholders of the Issuer and others about the Issuer and the Reporting Persons&rsquo; investment, making suggestions
and/or proposals concerning the Issuer&rsquo;s capitalization, ownership structure, operations, prospects, business and financial strategies,
strategic transactions, assets and liabilities, business and financing alternatives, the structure and composition of the Board, and such
other matters as the Reporting Persons may deem relevant to their investment in the Issuer, selling some or all of their Shares in the
open market or otherwise, engaging in short selling of or any hedging or similar transaction with respect to the Shares, acquiring additional
Shares and/or other equity, debt, notes, other securities, or derivative or other instruments that are based upon or relate to the value
of securities of the Issuer, or changing their intention with respect to any and all matters referred to in Item 4.<I>&rdquo;</I></P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 8pt"><B>Important Additional Information and Certain Information Concerning the
Participants</B></P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">On May 9, 2022, the JDS1 Group filed a revised preliminary
proxy statement and an accompanying revised preliminary GOLD proxy card with the SEC to be used to solicit proxies from the Company&rsquo;s
stockholders in connection with the 2022 Annual Meeting to have stockholders elect three director nominees to the Company&rsquo;s Board
of Directors (the &ldquo;<U>Board</U>&rdquo;) and approve a non-binding proposal requesting that the Board take the necessary steps to
declassify the Board (in a manner that does not affect the unexpired terms of the previously elected directors) so that all directors
are elected on an annual basis, with such declassification of the Board done in the most expeditious manner available under the Delaware
General Corporation Law.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">THE JDS1 GROUP STRONGLY ADVISES ALL STOCKHOLDERS OF
THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTPS://WWW.SEC.GOV.
IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON
REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS&rsquo; PROXY SOLICITOR.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">The participants in the proxy solicitation are anticipated
to be JDS1, LLC, a Delaware limited liability company, CCUR Holdings, Inc., a Delaware corporation, CIDM II, LLC, a Delaware limited liability
company, Julian D. Singer, David S. Oros, Shelly C. Lombard, Matthew Stecker, and Igor Volshteyn.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">As of the date hereof, JDS1, LLC beneficially owns
directly 1,131,577 shares of Common Stock, par value $0.001 per share, of the Company (the &ldquo;<U>Common Stock</U>&rdquo;), including
500 shares of Common Stock held in record name. As of the date hereof, CCUR Holdings, Inc. beneficially owns directly 883,255 shares of
Common Stock. JDS1, LLC, as an affiliate of CCUR Holdings, Inc., may also be deemed to be the beneficial owner of the 883,255 shares of
Common Stock held by CCUR Holdings, Inc. As of the date hereof, CIDM II, LLC does not directly own any shares of Common Stock, but, as
the asset manager to CCUR Holdings, Inc., may be deemed the beneficial owner of the 883,255 shares of Common Stock beneficially owned
by CCUR Holdings, Inc. As of the date hereof, Mr. Singer does not directly own any shares of Common Stock, but may be deemed to have beneficial
ownership of the Common Stock as a result of being the managing member of each of JDS1 and CIDM II, LLC and an affiliate of CCUR Holdings,
Inc. Accordingly, Mr. Singer may be deemed to beneficially own (i) the 1,131,577 shares of Common Stock beneficially owned directly by
JDS1, LLC, and (ii) the 883,255 shares of Common Stock beneficially owned directly by CCUR Holdings, Inc. As of the date hereof, Mr. Oros
directly beneficially owns 388,600 shares of Common Stock. As of the date hereof, none of Ms. Lombard and Messrs. Stecker and Volshteyn
beneficially owned any shares of Common Stock.</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
